Diabetes Mellitus: Types, Risk Factors & Evidence-Based Management

Diabetes mellitus = chronic hyperglycemia from insulin deficiency (Type 1), insulin resistance (Type 2), or other causes. Global prevalence: 537M adults (2021); projected 783M by 2045.

Classification

TypePathophysiologyOnsetTreatment
Type 1 (5–10%)Autoimmune β-cell destruction → absolute insulin deficiencyChildhood/young adult (any age)Insulin lifelong (basal-bolus or pump)
Type 2 (90–95%)Insulin resistance + progressive β-cell failureAdult (increasing in youth)Lifestyle → metformin → add-ons (SGLT2i, GLP-1 RA, insulin)
Gestational (GDM)Placental hormones → insulin resistance in pregnancy24–28 wks gestationDiet/exercise → insulin if needed
Other (MODY, LADA, drug-induced, pancreatic)Specific genetic/secondary causesVariableTailored

Major Risk Factors (Type 2)

  • Obesity (BMI ≥25, ≥23 Asian), visceral adiposity
  • Sedentary lifestyle, age ≥45
  • Family history (1st degree: 2–6× risk)
  • Ethnicity: Black, Hispanic, Native American, Asian, Pacific Islander
  • GDM history, PCOS, hypertension, dyslipidemia, NAFLD

Management Pillars

  1. Lifestyle: ADA nutrition therapy (Mediterranean/DASH/plant-based), 150 min/week moderate activity, 7–9% weight loss if overweight.
  2. Glucose-lowering: Metformin first-line unless contraindicated. Cardio-renal benefit agents (SGLT2i, GLP-1 RA) preferred early if ASCVD, HF, CKD, or high risk.
  3. Targets: HbA1c <7% (individualized), TIR >70% (CGM), BP <130/80, LDL <70 (ASCVD) or <100.
  4. Screening: Annual dilated eye, foot exam, UACR/eGFR, lipids.

Prevention

DPP/DPS trials: 58% risk reduction with 7% weight loss + 150 min/week activity in prediabetes. Metformin 31% reduction.

Diabetes - Related Articles